Literature DB >> 16505192

Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport.

Danielle Duffy1, Daniel J Rader.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16505192     DOI： 10.1161/CIRCULATIONAHA.105.593855

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  34 in total

Review 1.  The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids.

Authors:  Guo-Jun Zhao; Kai Yin; Yu-Chang Fu; Chao-Ke Tang
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

Review 2.  New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease.

Authors:  Philip J Barter; Rajesh Puranik; Kerry-Anne Rye
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

3.  When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.

Authors:  John F Oram; Jay W Heinecke
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

Review 4.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

Authors:  Emil M deGoma; Rolando L deGoma; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

Review 5.  Cardioprotective functions of HDLs.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  J Lipid Res       Date:  2013-06-27       Impact factor: 5.922

Review 6.  Proposed mechanism for lipoprotein remodelling in the brain.

Authors:  Chunjiang Yu; Katherine L Youmans; Mary J LaDu
Journal:  Biochim Biophys Acta       Date:  2010-05-12

7.  When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.

Authors:  John F Oram; Jay W Heinecke
Journal:  Curr Atheroscler Rep       Date:  2007-12       Impact factor: 5.113

8.  Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome.

Authors:  Lewis H Kuller; Gregory Grandits; Jerome D Cohen; James D Neaton; Ronald Prineas
Journal:  Atherosclerosis       Date:  2006-10-02       Impact factor: 5.162

Review 9.  Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation.

Authors:  Yan-Yun Liu; Gregory A Brent
Journal:  Trends Endocrinol Metab       Date:  2009-12-16       Impact factor: 12.015

10.  Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.

Authors:  John S Millar; Danielle Duffy; Ramprasad Gadi; LeAnne T Bloedon; Richard L Dunbar; Megan L Wolfe; Rajesh Movva; Ashish Shah; Ilia V Fuki; Mary McCoy; Cynthia J Harris; Ming-Dauh Wang; Daniel C Howey; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-11-06       Impact factor: 8.311
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.